DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius Kabi acquires Fenwal Holdings, Inc.

| Source: EQS Group AG EQS Group AG 

Fresenius SE & Co. KGaA  / Key word(s): Acquisition

20.07.2012 20:55

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Fresenius Kabi acquires Fenwal Holdings, Inc. 

Fresenius Kabi has signed a definitive agreement to acquire Fenwal
Holdings, Inc., a leading U.S.-based provider of transfusion technology
products for blood collection, separation and processing, from TPG and
Maverick Capital. In 2011, Fenwal had sales of US$614 million with an
adjusted EBITDA of US$90 million.

The acquisition marks another major step in Fresenius Kabi's growth
strategy. The company had announced previously that expanding its medical
devices/transfusion technology segment is a priority. Fresenius Kabi will
now become a global leader in transfusion technology.

Financial terms were not disclosed. The transaction will be financed
initially from existing funds, whereas the enterprise value does not exceed
the proceeds of the May 2012 capital increase.

The transaction is subject to the necessary regulatory approvals by the
relevant antitrust authorities, and is expected to close at the end of
2012.

Fresenius SE & Co. KGaA, 
represented by Fresenius Management SE, 
Board of Management

Bad Homburg v.d.H., July 20, 2012

End of note


20.07.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Fresenius SE & Co. KGaA
              Else-Kröner-Straße 1
              61352 Bad Homburg v.d.H.
              Germany
Phone:        +49 (0)6172 608-2485
Fax:          +49 (0)6172 608-2488
E-mail:       ir-fre@fresenius.com
Internet:     www.fresenius.com
ISIN:         DE0005785604
WKN:          578560 
Indices:      DAX
Listed:       Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard),
              München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart;
              Terminbörse EUREX
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------